News | February 16, 2024
Marksans Q3 FY24 revenue up 22% at Rs 586 Cr
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
The talk show will be held monthly via Medanta's YouTube, Facebook and LinkedIn channe
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
The company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies
The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
This recognition attests to Sun Pharma’s commitment to incorporate Environmental, Social, and Governance (ESG) principles through focused initiatives across its businesses
These re-agent and diagnostic test kits come with 99.7% accuracy
The 200 bedded hospital owned & operated by Alexis
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
Subscribe To Our Newsletter & Stay Updated
